Best Pharmacology Journals (2026): Ranked by Impact and Accessibility

If you want mechanistic pharmacology readers, submit to British Journal of Pharmacology, JPET, Molecular Pharmacology, or Biochemical Pharmacology. If you want clinical drug-response readers, choose Clinical Pharmacology & Therapeutics. If the manuscript is a review, choose a review journal before treating those titles as primary-research targets.

Evidence basis: this guide was updated from current JCR context, SCImago category context, BPS/Wiley, ASCPT/Wiley, ASPET, Frontiers, existing Manusights drug-discovery and pharmacology-adjacent pages, and Manusights internal analysis of receptor pharmacology, dose-response studies, drug metabolism, pharmacokinetics, translational drug-response, resistance, and molecular mechanism manuscripts.

Across our pre-submission review work on pharmacology manuscripts, the recurring problem is not that authors pick weak journals. It is that they pick the right prestige tier for the wrong kind of evidence. A clinical dosing study, a receptor-mechanism paper, a broad drug-discovery review, and a classical in vivo pharmacology paper may all use the word pharmacology, but they fail editorial triage for different reasons.

In our analysis of pharmacology manuscripts, three specific failure patterns create most journal-fit problems. We see manuscripts overstate clinical relevance before the dosing, PK/PD, comparator, and endpoint logic is visible, and in practice this sends otherwise useful papers to the wrong pharmacology audience.

Clinical pharmacology claim without clinical pharmacology evidence. CPT and clinical pharmacology venues need the abstract, methods, cohort description, dosing logic, pharmacokinetic or pharmacodynamic endpoint, and statistical analysis to make the human drug-response question visible. A biomarker association or small retrospective subgroup is not enough if the paper claims dosing, safety, or regulatory relevance.

Check whether your clinical pharmacology framing fits ->

Mechanistic pharmacology without clean controls. BJP, JPET, Molecular Pharmacology, and Biochemical Pharmacology reward mechanism, but the figures and methods must show dose-response logic, controls, comparator compounds, pathway specificity, model choice, and statistical design. A strong effect size can still read weakly if the first figure hides concentration, timing, or control structure.

Check whether your pharmacology methods are strong enough ->

Drug-discovery framing before the manuscript earns it. Review journals and drug-discovery venues expect the manuscript to connect mechanism, target, compound, disease context, and translational path. Pharmacology papers often overstate therapeutic promise from one model, one assay, or one compound series when the discussion should stay closer to mechanism.

Check whether your therapeutic claim is overreaching ->

This guide tells you what pharmacology journals and communities look for across the journal set; the review tells you whether YOUR paper passes the mechanism, dosing, controls, model, statistical, clinical, and audience-fit checks before upload. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

1. Nature Reviews Drug Discovery

Nature Reviews Drug Discovery and Pharmacological Reviews are not ordinary primary-research targets. Their citation strength comes from synthesis, topic selection, and long shelf life. They matter when the manuscript is a review or proposal-level synthesis, not when the paper reports a new assay result.

Submit here only when the article is a commissioned or clearly field-shaping synthesis. Think twice if the manuscript reports original primary data, one compound series, or one assay workflow; those papers usually belong in a primary pharmacology or drug-discovery journal.

2. Pharmacological Reviews And Trends In Pharmacological Sciences

Pharmacological Reviews fits long, authoritative reviews that can synthesize a full pharmacology field. Trends in Pharmacological Sciences fits shorter conceptual reviews and opinion-style pieces when the topic is timely and the argument is sharp.

These venues require authority and synthesis, not just a complete literature search. If the manuscript cannot explain what the field now understands differently, it is probably not ready for a high-profile review journal.

3. British Journal Of Pharmacology

British Journal of Pharmacology is a high-signal target for primary pharmacology because it rewards experimental rigor. It is a better choice than a higher-metric review venue when the paper's contribution is mechanistic data rather than field synthesis.

Choose BJP when receptor biology, pathway mechanism, translational pharmacology, experimental design, and reporting quality are the manuscript's strengths. The paper should make randomization, blinding, controls, group size, dose-response logic, and model choice visible enough for methods-focused review.

4. Clinical Pharmacology & Therapeutics

Clinical Pharmacology & Therapeutics is strongest when the drug question is human and decision-relevant: dosing, pharmacokinetics, pharmacodynamics, pharmacogenomics, therapeutic response, safety, or regulatory science.

Use CPT when the central claim changes how readers understand human drug response, dosing, biomarker interpretation, safety, pharmacogenomics, or regulatory decisions. If the paper is mostly cell biology with a clinical paragraph added later, a mechanistic pharmacology journal is likely cleaner.

5. JPET, Molecular Pharmacology, And Biochemical Pharmacology

JPET, Molecular Pharmacology, and Biochemical Pharmacology remain important because pharmacology is not only citation metrics. Many papers need the audience that understands receptor function, pathway perturbation, enzyme kinetics, model choice, and dose-response evidence.

Choose JPET for classical experimental pharmacology and dose-response logic, Molecular Pharmacology for receptor or pathway mechanism, and Biochemical Pharmacology when molecular or cellular drug mechanism is the protagonist. These titles can be better than a broader journal when the evidence package is technical and pharmacology-specific.

6. European Journal Of Pharmacology

European Journal of Pharmacology is a broad original-research route for solid pharmacology that does not need flagship selectivity. It can fit in vivo, in vitro, mechanistic, translational, or systems-adjacent pharmacology when the paper is useful but not field-defining.

This is often a realistic target when the study is rigorous, the claim is appropriately scoped, and the authors need a broad pharmacology audience rather than a highly specialized receptor, clinical, or biochemical venue.

7. Frontiers In Pharmacology

Frontiers in Pharmacology is a broad open-access route. It can be reputable when section fit, article type, indexing, fee, and evidence depth are sound, but it is not a substitute for matching the manuscript to the right pharmacology audience.

Use it when OA reach and section fit are central to the strategy. Think twice if a society journal such as BJP, JPET, Molecular Pharmacology, or Pharmacology Research & Perspectives would send a clearer signal to the exact reviewer community.

8. Pharmacology Research & Perspectives

Pharmacology Research & Perspectives is a society-backed open-access pharmacology route. It can be a strong fit when transparency, rigor, reproducibility, and clear pharmacological interpretation matter more than novelty-based triage.

Choose this route for careful pharmacology studies that deserve the right field audience but do not need a prestige-driven flagship claim. It is especially useful when methods quality and interpretability are stronger than headline novelty.

Submit when the manuscript's strongest evidence matches the journal's reader.

• BJP: submit if the study is mechanism-driven and the experimental design is strong enough for method-focused review.
• CPT: submit if the central contribution concerns human drug response, dosing, PK/PD, pharmacogenomics, or regulatory science.
• JPET: submit if classical experimental pharmacology, dose-response evidence, and model relevance are the paper's strengths.
• Biochemical Pharmacology: submit if drug mechanism at the molecular or cellular level is the real contribution.
• European Journal of Pharmacology: submit if the paper is broad, solid pharmacology but not a flagship mechanistic story.
• Frontiers in Pharmacology: submit if open-access reach and section fit matter more than society-journal signaling.
• Pharmacology Research & Perspectives: submit if rigor and transparency are stronger than novelty.

• Separate review journals from original-research journals. Review titles often dominate rankings but may be irrelevant to your primary-data manuscript.
• Name the pharmacology unit. Is the paper about a receptor, pathway, compound, dose, human response, metabolism route, adverse effect, resistance mechanism, or therapeutic class?
• Match evidence to journal culture. BJP and JPET care about experimental design; CPT cares about clinical pharmacology relevance; review journals care about synthesis and authority.
• Use exact metric pages for exact metrics. This page helps with shortlist fit; exact current JIF, APC, review-time, and acceptance-rate checks belong in JCR or journal-specific author pages.